Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Bites and Stings × Hydroxyurea × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycythemia Vera 5 Treatment-Refractory Solid Tumors 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Glioma 1 Glioblastoma 1 Bites and Stings 1

Interventions

pembrolizumab 3 enzalutamide 2 blinatumomab 2 abiraterone 2 Immune Checkpoint Inhibitors 2 Cytochrome P-450 Enzyme System 2 AMG 757 2 durvalumab 1 dostarlimab 1 cemiplimab 1 atezolizumab 1 N,N-dicyclohexyl-isoborneol-10-sulfonamide 1 Hydroxyurea 1 Etoposide 1 Etanercept 1 Carboplatin 1 Androgen Receptor Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06063317 2026-03-06

OASIS

Imugene Limited

Phase 1 Terminated

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon ⚡